Most scientists who wrote positive articles about a diabetes drug had financial ties to the drug’s maker, GlaxoSmithKline, according to a Mayo Clinic report published Thursday in the British Medical Journal. The researchers examined articles that came out after an analysis found that rosiglitazone, marketed by GSK as Avandia, was linked to a higher risk for heart disease.
From Bloomberg news:
Almost 90 percent of scientists who wrote positive articles, reviews or commentaries about Avandia had financial ties to London-based Glaxo, the study published in the British Medical Journal found.
“We aimed to determine whether financial conflicts of interest with pharmaceutical manufacturers could be fuelling this fire,” wrote the researchers, led by Amy Wang, a resident in internal medicine at the Mayo Clinic in Rochester, Minnesota. “From our findings, it appears that the answer is yes.’”
Read the study in the British Medical Journal.


